In8Bio Inc (INAB) Stock Price, Quote & News

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 600 6438

Website: in8bio.com

Address:

350 5th Avenue, Suite 5330, New York, United States

BioPharm_Swinger Jul. 28 at 2:17 PM

$INAB breaking out! All the indicators are there for a move to $4!

1 · Reply

FelixH86 Jul. 25 at 6:25 PM

$INAB close the week strong...2,45...

0 · Reply

Syyk Jul. 25 at 1:19 AM

$ADAP 🚀 One of the Most Underrated Biotech Plays Out There? 🚀 ------Undervalued stock 1️⃣ Despite launching a commercial product and generating real revenue, Adap’s market cap is sitting at just $70M–90M. That’s insanely low for a company with fundamentals! 2️⃣ Lete-cel has received FDA Breakthrough Therapy Designation, and a BLA rolling submission is expected by Q4 2025. Major commercial milestones ahead! 3️⃣ Analyst consensus: Mostly BUY ratings, with price targets ranging from $1.40 to $1.70+. 📊 Q1 2025 (March quarter) revenue came in at $7.3M, up 28% YoY — showing strong post-launch stability. 💡 TTM revenue is now $179.6M, up a massive 195% YoY — growth is real and accelerating. 👩‍🔬 Backed by ~506 employees, strong manufacturing capabilities (27-day avg turnaround, 100% success rate), and the commercial launch of TECELRA, this isn’t just a biotech dream — it’s a company with substance. $INAB $PSTV $LIDR $IXHL

3 · Reply

Picklerinthekitchen Jul. 24 at 1:58 PM

$INAB

0 · Reply

FelixH86 Jul. 24 at 1:39 PM

$INAB added...

0 · Reply

BioPharm_Swinger Jul. 23 at 8:20 PM

$INAB $4 is written all over this one when breaks out and volume comes in!

0 · Reply

BigSqueezeComing Jul. 23 at 3:58 PM

$INAB Get in early PT $3 multi day play.

0 · Reply

jacksparo Jul. 23 at 3:46 PM

$INAB If this breaks 2.60 then a lot might get exited about it !!

0 · Reply

Boobooboo Jul. 23 at 1:58 PM

$INAB 2.50 4.00

0 · Reply

dogood Jul. 23 at 11:58 AM

$FAMI all these are stuck after the reversal it, but they pulled it down $FAMI $CLRB $INAB should run back to $10 to $20 with great news

0 · Reply

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Jun 2, 2025, 7:30 AM EDT - 2 months ago

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

May 14, 2025, 8:00 AM EDT - 2 months ago

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 12, 2025, 8:00 AM EDT - 2 months ago

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 7, 2025, 4:00 PM EDT - 2 months ago

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 29, 2025, 8:00 AM EDT - 3 months ago

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Apr 28, 2025, 8:00 AM EDT - 3 months ago

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Mar 31, 2025, 8:00 AM EDT - 4 months ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mar 18, 2025, 8:05 AM EDT - 4 months ago

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Mar 13, 2025, 4:05 PM EDT - 4 months ago

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 3, 2025, 9:28 AM EST - 5 months ago

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Feb 26, 2025, 8:00 AM EST - 5 months ago

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 5 months ago

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 14, 2025, 9:00 AM EST - 5 months ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Feb 11, 2025, 8:00 AM EST - 5 months ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Dec 10, 2024, 7:00 AM EST - 8 months ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Nov 12, 2024, 4:26 PM EST - 9 months ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Sep 4, 2024, 4:01 PM EDT - 11 months ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Aug 29, 2024, 6:05 AM EDT - 11 months ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:05 AM EDT - 1 year ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Jun 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 13, 2024, 4:01 PM EDT - 1 year ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 3, 2024, 6:05 AM EDT - 1 year ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 10:00 AM EDT - 1 year ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 13, 2024, 8:00 AM EDT - 1 year ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 9, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Apr 30, 2024, 6:05 AM EDT - 1 year ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 16, 2024, 4:05 PM EDT - 1 year ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 9, 2024, 4:30 PM EDT - 1 year ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Mar 14, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 5, 2024, 4:30 PM EST - 1 year ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Feb 26, 2024, 8:00 AM EST - 1 year ago

IN8bio to Present at Upcoming Investor Conferences

Feb 14, 2024, 8:00 AM EST - 1 year ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Jan 4, 2024, 8:00 AM EST - 1 year ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Dec 11, 2023, 4:05 PM EST - 1 year ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Dec 11, 2023, 9:00 AM EST - 1 year ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Dec 7, 2023, 8:00 AM EST - 1 year ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 5, 2023, 8:00 AM EST - 1 year ago

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

Nov 20, 2023, 7:00 AM EST - 1 year ago

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

Nov 10, 2023, 7:00 AM EST - 1 year ago

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Nov 9, 2023, 4:00 PM EST - 1 year ago

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 8:00 AM EST - 1 year ago

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Nov 3, 2023, 12:00 PM EDT - 1 year ago

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Nov 2, 2023, 9:17 AM EDT - 1 year ago

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

Nov 1, 2023, 8:00 AM EDT - 1 year ago

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

Oct 12, 2023, 8:00 AM EDT - 1 year ago

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

Sep 29, 2023, 8:00 AM EDT - 1 year ago

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting

BioPharm_Swinger Jul. 28 at 2:17 PM

$INAB breaking out! All the indicators are there for a move to $4!

1 · Reply

FelixH86 Jul. 25 at 6:25 PM

$INAB close the week strong...2,45...

0 · Reply

Syyk Jul. 25 at 1:19 AM

3 · Reply

Picklerinthekitchen Jul. 24 at 1:58 PM

$INAB

0 · Reply

FelixH86 Jul. 24 at 1:39 PM

$INAB added...

0 · Reply

BioPharm_Swinger Jul. 23 at 8:20 PM

$INAB $4 is written all over this one when breaks out and volume comes in!

0 · Reply

BigSqueezeComing Jul. 23 at 3:58 PM

$INAB Get in early PT $3 multi day play.

0 · Reply

jacksparo Jul. 23 at 3:46 PM

$INAB If this breaks 2.60 then a lot might get exited about it !!

0 · Reply

Boobooboo Jul. 23 at 1:58 PM

$INAB 2.50 4.00

0 · Reply

dogood Jul. 23 at 11:58 AM

$FAMI all these are stuck after the reversal it, but they pulled it down $FAMI $CLRB $INAB should run back to $10 to $20 with great news

0 · Reply

Adamchristlover Jul. 23 at 3:27 AM

$OPEN $SLS $AKBA $VSTM $INAB Thank you Jack you saved me from losing big in this BS stock open. I appreciate the help man!

2 · Reply

MadMaverick Jul. 22 at 3:12 PM

$RNXT - Late July Phase III data targeting pancreatic cancer, echoing recent biotech surges: 🔹 $INAB +150% on gene therapy news 🔹 $TCRT +80% after CAR-T trial update 🔹 $RDHL +58% after FDA feedback for trial 🔹 $PMN +145% after Fast Track Designation news Looking for a technical breakout from descending channel attracting swing traders https://chartingdaily.com/RNXT-stock Communicated Disclaimer - Do your own research too.

2 · Reply

WallStreetIsNotEasy Jul. 21 at 7:46 PM

$INAB All they are doing is proving relapse free survival in hard to treat cancers and the Street says it’s valued around 7 million 👌 #cancerZero

0 · Reply

jacksparo Jul. 21 at 7:35 PM

$OPEN People burned here and for no reason other than fomo. While they could have traded great stocks like $SLS $AKBA $VSTM Even $INAB is much better and about to move up again ⚡️✅⚡️!

2 · Reply

MoneyMikey Jul. 21 at 5:48 PM

$INAB

0 · Reply

kadeee Jul. 21 at 5:19 PM

$LGVN Wide awake now!! $PMN $ATNF $INAB

0 · Reply

kadeee Jul. 21 at 2:53 PM

$LGVN I overslept and missed the pop. Hope she has juice left. $PMN $SABS $INAB

0 · Reply

KhalidsCapital Jul. 19 at 2:27 AM

RSLS is the quiet kind of setup that blindsides the market. Merger confirmed. Micro float. No dilution cloud. Biotech names like this don’t need hype they just need a headline. By the time it’s trending, the easy money will already be made. $TCON $BIVI $INAB $DRMA

0 · Reply

Market Cap	7.38M
Revenue (ttm)	0.00
Net Income (ttm)	-30.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	174,700
Avg Vol	257,986
Day's Range	N/A - N/A
Shares Out	3.03M
Stochastic %K	50%
Beta	0.00
Analysts	Strong Sell
Price Target	$2.00